00:00In Italy, 40% of diabetic patients have a chronic renal disease that leads to gradual
00:10renal damage, hypertension and cardiovascular problems to reach the terminal stage of the
00:15disease, i.e. dialysis or transplant.
00:17Today, thanks to FineRenone, which has obtained the free route of Haifa to reimbursement, patients
00:22with chronic renal disease associated with type 2 diabetes have a new therapeutic option
00:27that shows an anti-inflammatory and anti-fibrotic effect in the brain, heart and vases.
00:32The press conference talked about it towards a future absence of Bayer's dialysis.
00:37In addition to the inhibitor acids, the receptor antagonist of angiotensin, which we already
00:41know, there are the SGLT2, which are primary pharmaceuticals, and today we have the possibility
00:47of adding the FineRenone.
00:49This receptor antagonist of the corticosteroid hormone, which, however, is not steroid,
00:55has an anti-fibrotic, anti-protein, anti-progression effect of the renal disease and therefore
01:05it is a very important weapon that we have recently available to add it, obviously,
01:13to what we already have.
01:15FineRenone is the first non-steroidal selective antagonist of the receptors of corticosteroid
01:20minerals.
01:21The advantage of this new receptor antagonist is that it has a completely different structure
01:27and this means that it determines, following the bond with the receptor of these hormones,
01:34stimuli at the level of cytokines, of pro-inflammatory and pro-fibrotic substances of the inhibitor type.
01:43To confirm the effectiveness and safety of FineRenone, the Fidelio Registration Study.
01:48The Fidelio Study has shown that FineRenone is able to slow down the progression of renal
01:56damage in patients at very high risk and at high risk, in particular patients with a
02:03clearance between 25 and 75, with an albuminuria, an ACR between 30 and 5,000 mg.
02:12With FineRenone, Bayer enters a new therapeutic area, that of nephrology.
02:17It is very important because we have a history of research in various therapeutics and I think
02:24that our cardiovascular partnership is known to everyone.
02:28And today, finally, we also start to take care of the kidney, which we know is one of the
02:35most important organs in our body.
02:37And therefore, with FineRenone, we offer a concrete solution to the scientific community,
02:43but above all to Italian patients who need it the most.
Comments